BUZZ — Sandoz seen rising after it secures Canada approval for generic GLP — 1 shot
* Shares in Sandoz are indicated to rise 3% pre-market after Swiss generic drugmaker received regulatory approval for its generic semaglutide to treat type-2 diabetes in Canada * The injection is a generic version of Novo Nordisk's GLP-1 drug Ozempic, Sandoz says * The approval does not affect Sandoz's 2026 financial g